Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 154

Sort by

Sort Order Select

Journal Articles

Prognostic value of combining beta-2-microglobulin and total metabolic tumor volume in patients with follicular lymphoma: A post-hoc analysis of the relevance trial

Blood (2025) 146 (Supplement 1): 5361.

https://doi.org/10.1182/blood-2025-5361

Published: 2025

Journal Articles

Time-limited acalabrutinib monotherapy in frail patients with previously untreated chronic lymphocytic leukemia: Primary endpoint analysis of the randomized STAIR trial.

Blood (2025) 146 (Supplement 1): 684.

https://doi.org/10.1182/blood-2025-684

Published: 2025

Journal Articles

A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 icll-07 filo trial

Blood (2025) 146 (Supplement 1): 3883.

https://doi.org/10.1182/blood-2025-3883

Published: 2025

Journal Articles

MCL1 copy number gain is a recurrent mark of venetoclax resistance in patients with chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 3875.

https://doi.org/10.1182/blood-2025-3875

Published: 2025

Journal Articles

Center effect on large B-cell lymphoma outcome in frontline prospective Phase II and III trials : A lysa study

Tristan Robert-Van Houtteghem, Marguerite Fournier, Fabrice Jardin, Pierre Feugier, François Lemonnier, Loic Ysebaert, Franck Morschhauser, Laure Lebras, Cedric Rossi, Vincent Ribrag, Catherine Thieblemont, Aurelien Belot, Emmanuel Bachy

Blood (2025) 146 (Supplement 1): 4495.

https://doi.org/10.1182/blood-2025-4495

Published: 2025

Journal Articles

Dissecting complement pathway activation after allogeneic hematopoietic cell transplant: Results of a monocentric longitudinal monitoring program.

Camille Malbrun, Mélissa Julien, Antoine-Adrien Demasi, Emilie Darche, Gabrielle Roth-Guepin, Caroline Bonmati, Céline Kicki, Arnaud Campidelli, Anne Béatrice Notarantonio, Maud D'Aveni, Caroline Jacquet, Pierre Feugier, Christine André-Botté, Maxime Cravat, Tshinguta Mbuyi, Marcelo De Carvalho-Bittencourt, Marie-Thérèse Rubio, Simona Pagliuca

Blood (2025) 146 (Supplement 1): 6014.

https://doi.org/10.1182/blood-2025-6014

Published: 2025

Journal Articles

Glofitamab is superior to non a-CD3xC20 treatments for patients with diffuse large B-cell lymphoma who are refractory or relapse immediately after anti-CD19 CAR T-cell therapy: Final results of the bicar study (LYSA) and indirect comparison with a synthetic control arm from the descart registry.

Blood (2025) 146 (Supplement 1): 1958.

https://doi.org/10.1182/blood-2025-1958

Published: 2025

Journal Articles

Glofitamab for patients with Non–Large B-cell lymphoma refractory or relapsing after anti-CD19 CAR T-cell therapy: Final bicar study (LYSA) results.

Blood (2025) 146 (Supplement 1): 5923.

https://doi.org/10.1182/blood-2025-5923

Published: 2025

Journal Articles

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing

Blood blood.2025029999.

https://doi.org/10.1182/blood.2025029999

Published: 2025

Includes: Supplemental data

Journal Articles

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment

Blood (2025) 146 (8): 913–925.

https://doi.org/10.1182/blood.2024027727

Published: 2025

Includes: Supplemental data

Journal Articles

DNA Methylation Profiling Reveals Multiple Hits in MAPK Pathway in Triple Negative MDS/MPN with SF3B1 Mutation and Thrombocytosis

Marion Divoux, Ghislain Fievet, Natacha Dreumont, Laurence Schenone, Maud D'Aveni, Francois Girodon, Pierre Feugier, Sébastien Hergalant, Julien Broséus

Blood (2024) 144 (Supplement 1): 3174.

https://doi.org/10.1182/blood-2024-202925

Published: 2024

Journal Articles

Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial

Blood (2024) 144 (Supplement 1): 4505.

https://doi.org/10.1182/blood-2024-200614

Published: 2024

Journal Articles

Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa

Blood (2024) 144 (Supplement 1): 575.

https://doi.org/10.1182/blood-2024-202446

Published: 2024

Journal Articles

Prospective, Multicentric, Phase II Randomized Controlled Trial Comparing the Efficacy and Toxicity of Methotrexate to Cyclophosphamide in Large Granular Lymphocyte Leukemia: A French National Study (NCT01976182)

Thierry Lamy, Cedric Pastoret, Gandhi Damaj, Olivier Tournilhac, Emmanuel Bachy, Loic Ysebaert, Frederique Orsini Piocelle, Anne Banos, Marianne Schwarz, Estibaliz Lazaro, Pierre Feugier, Hugo Gonzalez, Alain Renault, Milena Kohn, Roch Houot, Mikael Roussel, Eric Bellissant

Blood (2024) 144 (Supplement 1): 979.

https://doi.org/10.1182/blood-2024-200266

Published: 2024

Journal Articles

Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study

Vincent Camus, Pierre Sesques, Alessio Bruscaggin, Daphne Krzisch, Mathieu Viennot, Luc-Matthieu Fornecker, Morgane Cheminant, Sébastien Bailly, Franck Morschhauser, Pierre Feugier, Sylvain Choquet, Eric Durot, Sylvain Carras, Caroline Delette, Gandhi Damaj, Agathe Waultier-Rascalou, Pierre Lebreton, Katell Le Du, Krimo Bouabdallah, Roch Houot, Stéphane Vigouroux, Kamel Laribi, Laure Lebras, Lucie Oberic, Sandy Amorim, Simone Bocchetta, Pierre-Julien Viailly, Vinciane Rainville, Philippe Ruminy, Melody Caillot, Lodovico Terzi Di Bergamo, Georgia Alice Galimberti, Maria Cristina Pirosa, Matin Salehi, Gabriela Forestieri, Fanny Drieux, Elena-Liana Veresezan, Alexandra Traverse-Glehen, Marie Donzel, Emilie Leveque, Lucie Burel, Elodie Bohers, Marie-Delphine Lanic, Pascaline Etancelin, Stéphanie Becker, Pierre Decazes, David Tonnelet, Simon Draye-Carbonnier, Hervé Tilly, Fabrice Jardin, Davide Rossi

Blood (2024) 144 (Supplement 1): 4354.

https://doi.org/10.1182/blood-2024-202508

Published: 2024

Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Blood (2024) 144 (Supplement 1): 584.

https://doi.org/10.1182/blood-2024-194593

Published: 2024

Journal Articles

Post-Therapeutic Tumor Losses of B-Cell Receptor Components CD20/CD19, a New Challenge in the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Thomas Hueso, Jessy Alchidiac, Maria-Rosa Ghigna, Arnaud Pages, Cyril Quivoron, Camille Bigenwald, Loic Renaud, Cristina Castilla-Llorente, Alexandre Eeckhoutte, Serge Bologna, Veronique Morel, Vincent Delwail, Pierre Feugier, Catherine Thieblemont, Olivier Bernard, Peggy Dartigues, Christophe Massard, Vincent Ribrag, Jean-Marie Michot

Blood (2024) 144 (Supplement 1): 474.

https://doi.org/10.1182/blood-2024-203664

Published: 2024

Journal Articles

Glofitamab Monotherapy in Patients with Non-Hodgkin B-Cell Lymphoma after Failing CAR T-Cell Infusion: Primary Analysis of the Bicar Study, a Phase II Lysa Study

Blood (2023) 142 (Supplement 1): 893.

https://doi.org/10.1182/blood-2023-177703

Published: 2023

Journal Articles

Verlen, “Very Elderly Rituximab Associated to Lenalidomide - Tafasitamab Combination in Frontline DLBCL Patients”, a Phase II Open-Label Study Evaluating Efficacy of Lenalinomide and Tafasitamab Combination Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older from the Lysa Group

Benoit Tessoulin, Julien Depaus, Pierre Feugier, Ludovic Fouillet, Julie Abraham, Sandy Amorin, Fabrice Jardin, Franck Morschhauser, Catherine Thieblemont, François-Xavier Gros, Bertrand Joly, Hacene Zerazhi, Sophie Bernard, Adrien Chauchet, Stéphane Vigouroux, Christophe Bonnet, Sarah Bailly, Steven Le Gouill

Blood (2023) 142 (Supplement 1): 3094.

https://doi.org/10.1182/blood-2023-173265

Published: 2023

Journal Articles

R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG

Blood (2023) 142 (Supplement 1): 435.

https://doi.org/10.1182/blood-2023-172951

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic value of combining beta-2-microglobulin and total metabolic tumor volume in patients with follicular lymphoma: A post-hoc analysis of the relevance trial

Time-limited acalabrutinib monotherapy in frail patients with previously untreated chronic lymphocytic leukemia: Primary endpoint analysis of the randomized STAIR trial.

A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 icll-07 filo trial

MCL1 copy number gain is a recurrent mark of venetoclax resistance in patients with chronic lymphocytic leukemia

Center effect on large B-cell lymphoma outcome in frontline prospective Phase II and III trials : A lysa study

Dissecting complement pathway activation after allogeneic hematopoietic cell transplant: Results of a monocentric longitudinal monitoring program.

Glofitamab is superior to non a-CD3xC20 treatments for patients with diffuse large B-cell lymphoma who are refractory or relapse immediately after anti-CD19 CAR T-cell therapy: Final results of the bicar study (LYSA) and indirect comparison with a synthetic control arm from the descart registry.

Glofitamab for patients with Non–Large B-cell lymphoma refractory or relapsing after anti-CD19 CAR T-cell therapy: Final bicar study (LYSA) results.

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment

DNA Methylation Profiling Reveals Multiple Hits in MAPK Pathway in Triple Negative MDS/MPN with SF3B1 Mutation and Thrombocytosis

Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial

Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa

Prospective, Multicentric, Phase II Randomized Controlled Trial Comparing the Efficacy and Toxicity of Methotrexate to Cyclophosphamide in Large Granular Lymphocyte Leukemia: A French National Study (NCT01976182)

Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Post-Therapeutic Tumor Losses of B-Cell Receptor Components CD20/CD19, a New Challenge in the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Glofitamab Monotherapy in Patients with Non-Hodgkin B-Cell Lymphoma after Failing CAR T-Cell Infusion: Primary Analysis of the Bicar Study, a Phase II Lysa Study

R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only